← Drug database

Kefdensis (denosumab)

BiosimilarAdditional monitoring
Region
🇪🇺 EU
Active substance
denosumab
Company
Stada Arzneimittel AG
Status
Authorised
Therapeutic area
Bone Resorption; Osteoporosis; Osteoporosis, Postmenopausal
CHMP opinion
Thu 18 Sep 2025
EU approval
Mon 17 Nov 2025
Designations
Biosimilar, Additional monitoring
Application
EMEA/H/C/006490
ATC
M05BX04
Official record
www.ema.europa.eu

Indication

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Kefdensis significantly reduces the risk of vertebral, non-vertebral and hip fractures.Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures (see section 5.1). In men with prostate cancer receiving hormone ablation, Kefdensis significantly reduces the risk of vertebral fractures.Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture (see section 5.1).

Regulatory milestones

Mon 17 Nov 2025🇪🇺 EU approval (EC decision)

Kefdensis (denosumab) approved in the EU

Marketing authorisation to Stada Arzneimittel AG; Biosimilar, Additional monitoring · source

Same substance in other markets

Follow Kefdensis

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.